Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A OREY

 Design  Primary endpoint –Confirmed virologic failure by W24 (2 consecutive HIV-1 RNA > 400 c/mL, or 3 consecutive HIV-1 RNA > 200 c/mL, or 4 consecutive HIV-1 RNA > 100 c/mL) Vernazza P, AIDS 2007;21: ATARITMO Open-label Single-arm Pilot trial HIV+ Conventional HAART > 6 months (stable during last 3 months) Or IDV/r monotherapy HIV-1 RNA 3 months No history of treatment failure N = 30 ATARITMO Study: Switch to ATV/r monotherapy Switch to ATV/r 300/100 mg qd* monotherapy W24 * Adjusted to 400/100 mg qd based on drug monitoring at W4

 Prior ARV therapy  Mean CD4 cell count at inclusion = 618/mm 3  2 virologic failures (7%)  Among 20 patients with plasma HIV-RNA 100 c/mL in 3  Conclusion –Limited pilot study, no control arm –Caution: risk of compartmentalisation of HIV RNA replication in the CSF Vernazza P, AIDS 2007;21: ATARITMO ATARITMO Study: Switch to ATV/r monotherapy IDV/r monotherapy9 3 NRTIs6 2 NRTIs + EFV10 2 NRTIs + PI/r5